Senesco Technologies, Inc. to Webcast, Live, at RetailInvestorConferences.com on June 7th
Published: Jun 07, 2012
NEW YORK, June 6, 2012 /PRNewswire/ -- Senesco Technologies, Inc. (NYSE: SNT), today announced that Leslie J. Browne, Ph.D., CEO & President, will present at RetailInvestorConferences.com.
June 7, 2012
3:00 PM EDT
www.retailinvestorconferences.com > red "register / watch event now" button
This will be a live, interactive online event where investors are invited to ask the company questions in real-time - both in the presentation hall as well as the company's "virtual trade booth." If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.
It is recommended that investors pre-register to save time and receive event updates.
About Senesco Technologies, Inc.
Senesco (SNT) is focused on developing cancer therapeutics. Its approach is new and based on its discovery that eIF5A, a novel pathway, has the ability to regulate programmed cell death and cell survival. Programmed cell death, or apoptosis, is a natural process that is used by the body to eliminate defective or diseased cells. SNS01-T is designed to selectively kill B-cell cancers like multiple myeloma, and, mantle cell and diffuse large cell lymphomas while leaving healthy cells unharmed.
Senesco is evaluating SNS01-T in patients with multiple myeloma. To date five patients have been enrolled into the Phase 1b/2a study. So far one patient has completed the 6 week dosing schedule. This patient's disease was considered stable, no disease progression, based on key disease markers including monoclonal protein when evaluated at the end of weeks 3 and 6. Two patients were withdrawn from the study due to disease progression, and two patients are currently being treated. No disease limiting toxicities have been recorded to date.
Senesco, a leader in eIF5A technology, is running a clinical study in multiple myeloma with its lead therapeutic candidate SNS01-T, which targets B-cell cancers by selectively inducing apoptosis by modulating eukaryotic, translation, initiation Factor 5A (eIF5A), which is believed to be an important regulator of cell growth and cell death. Accelerating apoptosis may have applications in treating cancer, while delaying apoptosis may have applications in treating certain inflammatory and ischemic diseases. Senesco has already partnered with leading-edge companies engaged in agricultural biotechnology and biofuels development, and is entitled to earn research and development milestones and royalties if its gene-regulating platform technology is incorporated into its partners' products.
Since 2010, RetailInvestorConferences.com, created by BetterInvesting (NAIC), PR Newswire, and MUNCmedia, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with retail investors using a graphically-enhanced online platform.
Designed to replicate the look and feel of location-based investor conferences, Retail Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network and MUNCmedia's sophisticated retail investor targeting.
SOURCE Senesco Technologies, Inc.